News
ADAG
3.800
-2.31%
-0.090
Weekly Report: what happened at ADAG last week (0413-0417)?
Weekly Report · 1d ago
Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers
TipRanks · 4d ago
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
TipRanks · 4d ago
Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026
Benzinga · 4d ago
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Barchart · 4d ago
Adagene Looks Attractive With ADG126 And Validating Partnerships
Seeking Alpha · 5d ago
Weekly Report: what happened at ADAG last week (0406-0410)?
Weekly Report · 04/13 10:18
Adagene Inc. - Depositary Receipt (ADAG) Price Target Increased by 11.46% to 11.57
NASDAQ · 04/09 03:43
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/08 17:05
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG), Caribou Biosciences (CRBU) and Praxis Precision Medicines (PRAX)
TipRanks · 04/07 10:10
Guggenheim Keeps Their Buy Rating on Adagene (ADAG)
TipRanks · 04/06 16:36
Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program
TipRanks · 04/06 13:15
Adagene Is Maintained at Buy by Guggenheim
Dow Jones · 04/06 12:05
Guggenheim Maintains Buy on Adagene, Raises Price Target to $10
Benzinga · 04/06 11:55
Adagene price target raised to $10 from $9 at Guggenheim
TipRanks · 04/06 10:45
Weekly Report: what happened at ADAG last week (0330-0403)?
Weekly Report · 04/06 10:18
Adagene announces pricing of $70M public offering of ADS
Seeking Alpha · 04/02 12:40
Adagene 18.666M share Spot Secondary priced at $3.75
TipRanks · 04/02 12:14
Adagene enters pact with Incyte for combination of muzastotug, INCA33890
TipRanks · 04/02 12:01
Adagene announces results from the latest data cut of muzastotug study
TipRanks · 04/02 11:55
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.